|Day Low/High||1.52 / 1.58|
|52 Wk Low/High||0.87 / 2.12|
Phase 2 study results presented at American Society of Hematology Annual Meeting on Saturday, December 3, 2016
Data to be presented on December 3, 2016; Abstract now available online
Live Webcast from New York on August 16th
MEI Pharma to receive $20 million in near-term cash payments, plus up to $444 million in potential milestone payments as well as royalties on future sales
Investors in MEI Pharma Inc saw new options begin trading this week, for the December 16th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 136 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
Median overall survival from Phase II study reached at 19.1 months
Data Presented at AACR Show Excellent PK/PD, Potential for Improved Therapeutic Window
MEI Pharma (MEIP) stock is surging in early-morning trading on Monday, after the oncology company announced positive results from its leukemia treatment's Phase II trial.
American Society of Hematology Annual Meeting Abstracts Now Available
Live Webcast from San Francisco on October 21st
Live Webcast from New York on August 11th
Live Webcast from New York on July 8th
Clinical Responses Continue to Improve; Median Overall Survival Not Yet Reached
Live Webcast from Las Vegas on May 13th
New Studies Identify Molecular Target, Mitochondria-Specific Effects of ME-344; Results from First-in-Human Clinical Study Published in Cancer
Shares of MEI Pharma (MEIP) were up in late morning trading Tuesday as investors swooped into the stock following its significant decline on Monday.
Shares of MEI Pharma (MEIP) plunged to a one-year low on Monday after the company announced its cancer drug Pracinostat failed to meet its main goal in a mid-stage trial.